Drug Profile


Alternative Names: BAY 44-4400; Macrofilaricide - Bayer Healthcare/Drugs for Neglected Diseases Initiative Foundation

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Bayer HealthCare; Drugs for Neglected Diseases Initiative Foundation
  • Class Antiparasitics
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Onchocerciasis

Most Recent Events

  • 27 Mar 2017 Bayer completes a phase I trial in Onchocerciasis (In volunteers) in United Kingdom (PO) (NCT02661178)
  • 11 Dec 2014 Emodepside licensed to Bayer Healthcare
  • 01 Jun 2013 Preclinical trials in Onchocerciasis in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top